The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Co. Still Compelling After Drug Trial Failure

Research Report
  ()
"Arcalyst remains the value driver" for Kiniksa Pharmaceuticals, and "we continue to hold a favorable view of the company," noted a Wedbush report.

Co. Looks To US For Help Fighting Strokes

  ()
Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs.

Co. Rated Outperform As Heart Failure Drug Nears Potential Approval

Research Report
  ()
"Cytokinetics' pipeline of muscle-directed therapies has potential to address several diseases with high unmet medical need and may generate significant revenue across pipeline programs," noted an Oppenheimer report.

Analyst: Question Lingers Over Biotech’s Cell Therapy

Research Report
  ()
A DawsonJames report notes that Brainstorm Cell Therapeutics’ autologous stem cells in amyotrophic lateral sclerosis will need further study to prove their effectiveness.

Coverage Initiated on Biopharma Co. After Turnaround Story

Research Report
  ()
"With Acasti Pharma shares trading near cash levels yet current resources sufficient to achieve key development milestones across the pipeline over 2022-2023, we recommend investors build a position," noted an Oppenheimer report.

Analyst Highlights Top Picks in Biotech for 2022

Research Report
  ()
Aldeyra Therapeutics, in the ophthalmology space, and SQZ Biotechnologies, in the cell therapy sector, have "advantages that their specific approaches allow," noted a BTIG report.

FDA Grants Approval for CNS-Focused Biopharma Firm's Bipolar Disorder Drug

  ()
Intra-Cellular Therapies Inc. shares traded 19% higher to a new 52-week high after the company reported the U.S. FDA has approved the use of its CAPLYTA® (lumateperone) for treatment of adults with bipolar depression.

Co. Launches Pivotal Phase in Alzheimer's Agitation Drug's Trial

Research Report
  ()
BioXcel Therapeutics' lead drug candidate for agitation in Alzheimer's disease patients could serve a substantial market, noted an H.C. Wainwright & Co. report.

Analyst Says Regeneron Could Be 'Biotech Champion'

Research Report
  ()
Regeneron Pharmaceuticals Inc.'s stock was up 36% in 2021 while the NASDAQ Biotechnology Index remained flat, Oppenheimer analyst Hartaj Singh reported in a Dec. 16 research note.

Co.'s Shares Gain 27% After FDA Nears Drug Approval

  ()
Shares of Calliditas Therapeutics AB traded higher after the company reported the U.S. FDA granted accelerated approval for its TARPEYO™ (budesonide) to reduce proteinuria in IgA nephropathy.

Target Price Raised on Biotech Based on Management Update

Research Report
  ()
During its recent R&D Day, Prometheus Biosciences announced new strong trial data, another new indication for its lead therapeutic candidate and progress in developing a subcutaneous formulation of it, according to an Oppenheimer report.

Arena Pharma Takes Center Stage With Pfizer's $6.7B Cash Buyout

  ()
Arena Pharmaceuticals shares traded 80% higher after the company reported it agreed to be acquired by Pfizer Inc. for $100.00 per share in cash in a deal valued at $6.7 billion.

Biopharma Explains How Its Technology Evolved, Describes Current Programs

Research Report
  ()
F-star Therapeutics "has methodically delivered scientific/preclinical/early clinical data validating its platform bispecific technology," noted an Oppenheimer report.

Biopharma's Anti-PD-L1 Antibody Advances in Two Oncologic Indications

Research Report
  ()
Checkpoint Therapeutics' "cosibelimab represents a competitive asset on both efficacy and safety with an expected added advantage of lower net price," an H.C. Wainwright & Co. report noted.

Biopharma Partners to Commercialize Enzyme Used for Kidney Transplant Patients

Research Report
  ()
The partnership allows Hansa Biopharma to "enter new markets without the cost and risk of building out country-specific commercial organizations for a single product," an H.C. Wainwright & Co. report indicated.

California-Based Biopharma Advances Lead Asset in COVID-19, Other Indications

Research Report
  ()
Humanigen has applications for lenzilumab in the works with U.S., United Kingdom and European drug regulatory agencies, noted a ROTH Capital Partners report.

CRO's Shares Rise 18% on Preliminary Q4/FY Financial Results

  ()
Shares of contract research organization Inotiv Inc. traded higher after the company reported select preliminary unaudited financial results for Q4/21 and FY/21 which included a 90.7% YoY increase in revenue and a 123.0% increase in gross profit.

Biopharma Seeks to Add Idiopathic Hypersomnia to Narcolepsy Drug's Label

Research Report
  ()
Harmony Biosciences Holdings intends to conduct a Phase Three trial next year to evaluate Wakix as a treatment for idiopathic hypersomnia, according to an Oppenheimer report.

Biopharma Launches Clinical Trial of Primary Asset in Endometrial Cancer

Research Report
  ()
"Solid tumors offers a substantial opportunity for Karyopharm Therapeutics' Xpovio (selinexor) that perhaps investors have not yet realized," noted an H.C. Wainwright & Co. report.

Phase Two Studies Start for Therapy for Chemo-Treated Breast Cancer Patients

Research Report
  ()
New clinical trials for G1 Therapeutics’ Cosela are “central to our investment thesis,” H.C. Wainright & Co. noted in a new research report.

Biotech Firm’s T-Cell Therapy Gets Positive Results in B-Cell Non-Hodgkin’s Lymphoma Study

  ()
Adicet Bio Inc. shares traded 37% higher after the company reported positive interim data from its Phase 1 GLEAN Study of ADI-001, which the firm noted is the first-ever allogeneic, off-the-shelf, gamma delta CAR T investigational cell therapy.

Biopharma Launches COVID Vaccine Program in South Africa & Mexico

Research Report
  ()
Oramed Pharmaceuticals' oral vaccine offers "convenience and safety advantages as well as coverage of emergent variant strains," noted a Nov. 29, 2021 H.C. Wainwright & Co. report.

Antibody-Drug Conjugate Developer Achieves High Objective Response Rates in Ovarian Cancer Study

  ()
ImmunoGen Inc. shares traded 30% higher after the company announced positive topline data from its pivotal Phase 3 SORAYA Trial of mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Emerging SARS-COv-2 Variant Is Revenue Growth Opportunity for Vaccine Developer

Research Report
  ()
Just a few days after the WHO deemed the COVID-19 Omicron variant a serious global health concern, leading mRNA-based vaccine developers BioNTech and Pfizer, along with rival Moderna, advised that if needed, the companies would be capable of developing a vaccine for the new mutating strains within roughly 100 days. H.C. Wainwright & Co. commented in a research note that it reiterates its "Buy" rating for BioNTech SE.

NRx Pharma's COVID-19 Vaccine Displays Effectiveness Against Delta Variant in Phase 2 Clinical Trial

  ()
Shares of NRx Pharmaceuticals Inc. traded 50% higher after the company commented on new data released by the Israel Institute for Biological Research regarding the effectiveness of its BriLife® COVID-19 Vaccine against the SARS-CoV-2 "Delta" variant.

Showing Results: 26 to 50 of 119 Prev Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"This is a great buy spot for LIO."
– Clive Maund, CliveMaund.com
"FABL has very nice sample results, up to 19.6% copper."
– Chen Lin, What Is Chen Buying? What Is Chen Selling?